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ABSTRACT
Objectives: To evaluate visual dysfunction and its
correlation with structural changes in the retina in
patients with Parkinson’s disease (PD).
Methods: Patients with PD (n=37) and controls
(n=37) were included in an observational cross-
sectional study, and underwent visual acuity (VA),
colour vision (using the Farnsworth and Lanthony
desaturated D15 colour tests) and contrast sensitivity
vision (CSV; using the Pelli-Robson chart and CSV
1000E test) evaluation to measure visual dysfunction.
Structural measurements of the retinal nerve fibre layer
(RNFL), and macular and ganglion cell layer (GCL)
thicknesses, were obtained using spectral domain
optical coherence tomography (SD-OCT). Comparison
of obtained data, and correlation analysis between
functional and structural results were performed.
Results: VA (in all different contrast levels) and all
CSV spatial frequencies were significantly worse in
patients with PD than in controls. Colour vision was
significantly affected based on the Lanthony colour
test. Significant GCL loss was observed in the
minimum GCL+inner plexiform layer. A clear tendency
towards a reduction in several macular sectors (central,
outer inferior, outer temporal and superior (inner and
outer)) and in the temporal quadrant of the RNFL
thickness was observed, although the difference was
not significant. CSV was the functional parameter most
strongly correlated with structural measurements in
PD. Colour vision was associated with most GCL
measurements. Macular thickness was strongly
correlated with macular volume and functional
parameters (r>0.70, p<0.05).
Conclusions: Patients with PD had visual dysfunction
that correlated with structural changes evaluated by
SD-OCT. GCL measurements may be reliable indicators
of visual impairment in patients with PD.
INTRODUCTION
Foveal vision alterations are associated with
Parkinson’s disease (PD), and seem to be
caused by dysfunction of the intraretinal
dopaminergic circuitry and final retinal
output to the brain.1 Recent studies demon-
strated retinal thinning in patients with PD
compared with healthy participants.2–5
Several studies report a correlation
between functional disability and axonal loss
observed in the optic nerve in multiple scler-
osis, another neurodegenerative process.6 7
Patient with PD are also reported to have
decreased contrast sensitivity and colour
vision, and altered visual evoked poten-
tials.1 8–13 To our knowledge, however, very
few studies have assessed visual dysfunction
in PD and its correlation with morphological
parameters.14 15
In the present study, we evaluated visual
acuity (VA), using an Early Treatment
Diabetic Retinopathy Study (ETDRS) chart,
Strengths and limitations of this study
▪ This study includes a complete assessment of
visual function parameters and the evaluation of
different retinal structures using spectral domain
optical coherence tomography in patients with
Parkinson’s disease.
▪ There are only two other published articles
evaluating the association between visual dys-
function and morphological parameters. Results
provided by these previous studies differ from
our results, possibly due to different measure-
ment methods and sample size.
▪ Colour vision in our study was assessed by
Lanthony and Farnsworth D15 colour tests,
which may provide more specific information
about colour deficiencies. These tests are not
commonly used to evaluate colour deficiencies
in patients with PD.
▪ An important limitation to our study is the inclu-
sion of one randomly selected eye per patient.
The incorporation of both eyes of each patient in
Parkinson’s disease studies is usually recom-
mended due to asymmetrical involvement of the
retina in this process.
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contrast sensitivity vision (CSV), using the CSV-1000E
test and Pelli-Robson chart, and colour vision, using the
Farnsworth and Lanthony tests in patients with PD and
healthy controls, to examine the association between
visual dysfunction and morphological parameters.
MATERIALS AND METHODS
Thirty-seven eyes of 37 patients with definite PD and 37
eyes of 37 age-matched and sex-matched healthy indivi-
duals were recruited for an observational cross-sectional
study. The study was performed at Miguel Servet
University Hospital in Zaragoza, Spain, and all evalua-
tions were performed in one single visit. All procedures
adhered to the tenets of the Declaration of Helsinki,
and all participants provided informed consent to par-
ticipate in the study.
The diagnosis of PD was based on standard clinical
and neuroimaging criteria.16 Information about disease
severity was assessed using the Hoehn-Yahr scale17 and
the Unified Parkinson Disease Rating Scale part III
score (UPDRS III).18 Disease duration and treatment
were recorded. Exclusion criteria were the presence of
significant refractive errors (>5 dioptres of spherical
equivalent refraction or 3 dioptres of astigmatism);
intraocular pressure≥21 mm Hg; media opacification;
concomitant ocular diseases, including history of glau-
coma or retinal pathology; and systemic conditions that
could affect the visual system. The healthy controls had
no history and no evidence of ocular or neurological
disease of any nature; their best-corrected VA (BCVA)
was >20/30 based on the Snellen scale.
All participants underwent a complete neuro-ophthal-
mic evaluation, which included pupillary, anterior
segment and funduscopic examination. Visual function
was assessed by evaluating BCVA, using an ETDRS chart,
CSV, using the CVS-1000E test and Pelli-Robson chart,
and colour vision, using the Farnsworth desaturated D15
and Lanthony desaturated D15 tests. Structural analysis
of the retina was performed using spectral domain (SD)
optical coherence tomography (OCT) with a Cirrus
high definition OCT (Carl Zeiss Meditec Inc, Dublin,
California, USA), which included three different proto-
cols: macular protocol (for macular thickness analysis),
retinal nerve fibre layer (RNFL) protocol and ganglion
cell protocol (for individual analysis of this layer).
LogMAR VA was evaluated at three different contrast
levels: 100% (HCVA, using ETDRS chart), 2.50% and
1.25% (LCVA, using Low-Contrast Sloan Letter Charts,
Precision Vision, LaSalle, Illinois, USA), with the per-
centage indicating the level of contrast, that is, 100%
representing black letters over white background and
1.25% representing light grey letters over white back-
ground. All measurements were obtained under mon-
ocular vision and controlled lighting conditions with
best correction.
Contrast sensitivity provides more complete informa-
tion about visual function than do VA tests. CSV was
evaluated in our patients, using the Pelli-Robson chart
and the CVS-1000E test. The Pelli-Robson chart com-
prises horizontal lines of capital letters organised into
groups of three (triplets), with two triplets per line.
Within each triplet, all letters have the same contrast.
The contrast decreases from one triplet to the next,
even within each line. All patients were evaluated under
both monocular and binocular vision at a distance of
1 m from the chart, and under controlled fotopic condi-
tions (85 cd/m2). The score corresponding to the last
triplet of letters seen by the patient was recorded.
The CSV-1000E instrument is used worldwide for stan-
dardised CSV and glare testing. All patients were evalu-
ated at a distance of 2.5 m from the chart, under
monocular vision, at four different spatial frequencies
(3, 6, 12 and 18 cycles per degree (cpd)). The chart
comprises four rows with 17 circular patches each. The
patches present a grating that decreases in contrast,
moving from left to right across the row. The patient
indicates whether the grating appears in the top patch
or the bottom patch for each column. Each contrast
value for each spatial frequency was transformed into a
logarithmic scale according to standardised values.
Colour vision was assessed using the Color Vision
Recorder (CVR) program. CVR software analyses chro-
matic discrimination by classification of colours. The
program includes the classic test of Farnsworth 100-hue
(FM-100), Farnsworth–Munsell D15 and Lanthony D15.
All patients in the study were evaluated using the
Farnsworth–Munsell D15 and Lanthony D15 protocols,
and different output parameters such as the confusion
index (C-index), the colour confusion index (CCI), the
confusion angle (Conf Ang) and the scatter index
(S-index) were recorded.19 20 The tests were performed
under monocular vision.
Structural measurements of the retina were obtained
using the Cirrus OCT device. The same experienced
operator performed all scans and did not apply manual
correction to the OCT output. We used an internal fix-
ation target because it provides the highest reproducibil-
ity and rejected poor quality scans prior to data analysis.
The Cirrus OCT macular cube 512×128 protocol pro-
vides a macular volume measure and retinal thickness
values for nine areas. These areas include a central
1 mm circle representing the fovea, and inner and outer
rings measuring 3 and 6 mm in diameter, respectively.
The inner and outer rings are divided into four quad-
rants each. The Cirrus OCT optic disc protocol gener-
ates images with 200 linear scans enabling analysis of the
RNFL of a 6 mm3 area around the optic nerve. For each
scan series of RNFL measurements, we assessed the
average, superior, inferior, temporal and nasal thickness.
Cirrus segmentation analysis for retinal layers also pro-
vides measurements of the ganglion cell layer (GCL)
thickness, evaluating six areas of the macular cube
(superior, superonasal, inferonasal, inferior, inferotem-
poral and superotemporal sectors), and measurements
of the average and minimum GCL plus the inner
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plexiform layer (GCL+IPL) value of a set of 360 spokes,
where each average represents the mean number of the
pixels along the spoke that lies within the measurement
annulus. The minimum is selected because the thinnest
portion of the GCL+IPL in the perifoveal region is con-
sidered to indicate damage to the ganglion cells.
All data analyses were performed using SPSS software
V.20.0 (SPSS Inc, Chicago, Illinois, USA). Owing to the
parametric distribution of the data, differences between
evaluations of patients with PD and healthy participants
were compared using Student’s t test. To avoid a high
false-positive rate, the Bonferroni correction for multiple
comparisons was calculated. The level of significance for
each variable was established based on Bonferroni
calculations.
The linear correlation between structural and func-
tional parameters was determined using Pearson’s cor-
relation coefficient. Values of p<0.05 were considered to
indicate a significant correlation. Each eye was consid-
ered separately, and one eye from each patient was ran-
domly selected for analysis.
RESULTS
Thirty-seven patients with PD and 37 healthy controls
were included in the study. The mean age of the
patients with PD was 69 years (range 58–74 years) and
the mean age of the healthy controls was 68 years
(range 60–76 years). Age (p=0.361), sex (p=0.441) and
intraocular pressure (p=0.720) did not differ signifi-
cantly between healthy controls and patients with PD.
Mean time from diagnosis of PD was 13.2 years. The
median Hoehn-Yahr stage was 2.7, and the stage of PD
based on the UPDRS III was 25.06 (range 7–39; table 1).
Treatment was divided into three different categories:
‘drugs that enhance dopamine levels’ (carbidopa, levo-
dopa and rasagiline), ‘dopaminergic drugs’ (pramipex-
ole, ropirinol and rotigotine) and ‘other’(amitriptiline,
propranolol and clonazepam). ‘Drugs that enhance
dopamine levels’ was the most prescribed category (89%
of patients), and combination therapy with levodopa
and carbidopa was the most frequent treatment (44%).
Sixty-four per cent of treatments were categorised as
‘dopaminergic’, most of which were used in combin-
ation with drugs included in the previous category. A
small percentage of patients (9%) were prescribed drugs
with no dopaminergic effects.
Functional parameters
Patients with PD had a lower BCVA at all three contrast
levels of the ETDRS chart compared with the controls
(0.18±0.26 in patients vs −0.065±0.9 in controls at 100%,
p=0.001; 0.59±0.21 vs 0.44±0.13 at 2.50%, p=0.010; and
0.61±0.23 vs 0.58±0.16 at 1.25%, p=0.009). CSV was
affected in patients at all four spatial frequencies of the
CSV 1000E chart (3, 6, 12 and 18 cpd) when analysed
based on the number of correct localised gratings
(p=0.001, p<0.001, p<0.001 and p=0.004, respectively).
The Pelli-Robson results also revealed a significant
reduction in CSV in patients with PD (1.71 in patients vs
1.89 in controls, p=0.02). Colour vision (Conf Angle in
Lanthony test) was also affected in PD. The results are
shown in table 2.
Structural parameters
Based on Bonferroni corrections, OCT measurements
indicated a significant difference in the minimum GCL
+IPL value (80.18±6.19 vs 82.45±3.60 µm; p=0.005).
However, we observed a clear tendency towards a reduc-
tion in superior macular sectors in the outer inferior,
outer temporal and central macular thickness in patients
with PD compared with controls: the p value for these
variables was <0.05 but did not meet Bonferroni signifi-
cance (results are shown in table 2). The segmentation
analysis revealed a tendency towards reduced GCL in
patients with PD in the superior (81.64±7.08 µm in
patients vs 84.55±4.32 µm in controls; p=0.032) and
superonasal sectors (81.04±7.23 vs 85.28±4.78 µm;
p=0.029); and the RNFL was reduced in the temporal
quadrant in patients with PD (table 3). These para-
meters, however, did not meet the level of significance
established by Bonferroni correction.
Correlation between functional and structural parameters
CSV was the functional parameter most frequently asso-
ciated with structural measurements in PD. The
Pelli-Robson CSV results correlated with GCL thickness
in all sectors, although the association was not strong
(r<0.5). The superonasal (r=0.40, p=0.010), inferonasal
(r=0.40, p=0.010), inferior (r=0.43, p=0.005),
Table 1 Epidemiological and disease characteristics of patients with PD and healthy participants, and statistical significance (p)
Parameter Controls Parkinson disease p Value
Number of eyes (n) 37 37 –
Age, years, range 68 (60–76) 69 (58–74) 0.361
Men:women (% of men) 24:13 (64.9) 23:14 (62.2) 0.441
Intraocular pressure 15.58 (2.71) 15.12 (2.98) 0.720
Disease duration, years, mean (SD) – 13.2 (5.77) –
Hoehn-Yahr, mean (SD) – 2.7 (0.64) –
UPDRS III, mean (SD) – 25.06 (8.24) –
UPDRS III, Unified Parkinson Disease Rating Scale part III.
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superotemporal sector (r=0.43, p=0.006) and average
GCL+IPL (r=0.45, p=0.004) values had the highest corre-
lations. The Pelli-Robson results also correlated with the
thickness in different sectors of the RNFL (average,
superior and inferior sectors). Measurements with the
CSV 1000E at different spatial frequencies correlated sig-
nificantly with most GCL measurements. The superona-
sal (r=0.40, p=0.013) and superotemporal (r=0.44,
p=0.006) thickness, average GCL+IPL thickness (r=0.40,
p=0.012) and the minimum GCL+IPL (r=0.40, p=0.011)
at a spatial frequency of 6 cpd; and the superotemporal
(r=0.41, p=0.01) thickness and the minimum GCL+IPL
thickness (r=0.43, p=0.006) at a spatial frequency of
18 cpd, had the strongest correlations between CSV
1000E and GCL thickness. Spatial frequencies of 6 and
18 cpd were strongly correlated with average macular
thickness (r=0.79, p=0.012; r=0.77, p=0.016, respectively)
and macular volume (r=0.78, p=0.013; r=0.78, p=0.014,
respectively, figure 1).
Colour vision assessed by the Lanthony test was also
associated with the structural parameters: the C-index
and CCI results were significantly correlated with all
outer macular parameters and most of the GCL mea-
surements (see table 4). A significant association
between colour vision and the RNFL parameters was
only found in isolated sectors (see table 4).
The strongest correlation was between the average
macular thickness and macular volume, and the Lanthony
CCI, C-index and S-index results. No significant
correlations were found between the Farnsworth’s test
parameters and structural measurements.
The VA ETDRS results correlated strongly with average
macular thickness and macular volume (see table 5,
figures 2 and 3). There were significant but mild associa-
tions between the GCL parameters and VA at 100%
(superonasal, inferonasal and average GCL+IPL thick-
ness, r=−0.38, p=0.016; r=−0.35, p=0.016; and r=0.35,
p=0.029, respectively) and 2.50% (superonasal sector, r=
−0.36, p=0.023).
There was a significant correlation between
Hoehn-Yahr score and VA contrast level 2.50% (r=0.48,
p=0.040), and CS measured with CSV 1000 at a space
frequency of 12 cpd (r=−0.59, p=0.038). No correlations
were detected between structural and disease severity
parameters.
DISCUSSION
In the present study, we evaluated the visual function
parameters, and assessed the association between visual
dysfunction and morphological changes in the retina of
37 patients with PD. Parameters corresponding to VA at
different contrast levels, and all CSV test results, were
altered in patients with PD in comparison with healthy
participants, prior to and after statistical correction for
multiple tests. Moreover, contrast sensitivity was the most
affected parameter in our study and correlated with
most of the structural data. Colour vision was measured
Table 2 Mean and SD of visual functional parameters in healthy controls and participants with Parkinson’s disease
Healthy controls
Parkinson’s disease
patients
Mean SD Mean SD Significance (p)
VA ETDRS 100 −0.06 0.096 0.18 0.26 0.001*
VA ETDRS 2.5 0.44 0.13 0.59 0.22 0.010*
VA ETDRS 1.25 0.58 0.16 0.62 0.23 0.009*
Pelli-Robson 1.89 0.11 1.71 0.17 0.002*
CSV 1000 3 cpd 1.72 0.16 1.49 0.35 0.001*
CSV 1000 6 cpd 1.94 0.13 1.62 0.34 <0.001*
CSV 1000 12 cpd 1.62 0.17 1.26 0.41 <0.001*
CSV 1000 18 cpd 1.11 0.22 0.73 0.34 0.004*
Farnsworth AC CCI 1.11 0.22 0.73 0.34 0.851
Farnsworth C-index 1.10 0.20 1.24 0.42 0.093
Farnsworth CCI 1.07 0.12 1.14 0.24 0.110
Farnsworth Conf Angle 63.90 11.15 65.84 7.49 0.392
Farnsworth S-index 1.56 0.22 1.64 0.39 0.278
Farnsworth time 78.67 28.96 82.91 33.10 0.616
Lanthony AC CCI 1.05 0.19 1.02 0.18 0.489
Lanthony C-index 1.43 0.39 1.64 0.53 0.058
Lanthony CCI 1.30 0.23 1.44 0.37 0.066
Lanthony Conf Angle 62.31 14.74 71.91 9.25 0.002*
Lanthony S-index 1.69 0.43 1.95 0.48 0.020
Lanthony time 77.14 25.99 84.09 39.31 0.431
The asterisk indicates those values with statistical significance after Bonferroni correction for multiple tests (p<0.0125 for VA ETDRS 100,
2.50 and 1.25; p<0.0125 for Pelli-Robson and CSV 1000E measurements; p<0.0083 for Farnsworth and Lanthony tests).
AC CCI, age-corrected colour confusion index; CCI, colour confusion index; C-index, confusion index; Conf Angle, confusion angle; cpd,
cycles per degree; ETDRS, Early Treatment Diabetic Retinopathy Study; PD, Parkinson’s disease; S-index, scatter index; VA, visual acuity.
4 Polo V, et al. BMJ Open 2016;6:e009658. doi:10.1136/bmjopen-2015-009658
Open Access
group.bmj.com on September 20, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
using two different tests, the Farnsworth and Lanthony
15 D tests. These tests provide information for differenti-
ating participants with severe loss of colour vision from
those with milder colour defects or normal colour
vision, and also can be used to evaluate acquired loss of
colour vision. In our study, only the Lanthony Conf Ang
was significantly altered in patients with PD. The
Lanthony test is less saturated than the Farnsworth
colour test, thus it is designed to detect more subtle
colour deficiencies. Our patients performed worse than
controls in both tests (higher C-index and S-index,
reaching ranges similar to protanomalies) although
these differences did not reach statistical significance as
established by Bonferroni correction. Lanthony S-index
p value was <0.05, indicating that our patients had a
(subtle) tendency to protanomaly (S-index of 1.95).
One important limitation of this study is that only one
eye was tested per person. Some recent studies suggest
asymmetrical involvement of the retina in PD and rec-
ommend the incorporation of both eyes of each patient
in the study.21 Thus, the diagnostic yield in this study
may have been lowered by including a potentially lesser
affected eye. In a similar way, including a randomly
selected eye could be inappropriate for other neuro-
logical conditions, for example, a tumour compressing
one optic nerve. However, incorporating both eyes of a
patient may sometimes be controversial since minimum
symmetric structural and functional alterations could
Table 3 Mean and SD of structural parameters (RNFL, GCL and macular thicknesses) obtained with the Cirrus HD optical
coherence tomography device in healthy controls and participants with Parkinson’s disease
Controls Parkinson’s disease
Structural parameters Mean SD Mean SD p Value
Macular measurements
Central macular thickness 254.75 17.903 248.96 17.765 0.028
Inner superior macular thickness 327.34 13.094 325.73 19.329 0.019
Inner nasal macular thickness 328.52 13.263 325.45 17.098 0.091
Inner inferior macular thickness 326.14 13.179 324.82 17.921 0.106
Inner temporal macular thickness 315.90 13.615 312.82 15.760 0.945
Outer superior macular thickness 284.76 9.418 279.44 17.981 0.008
Outer nasal macular thickness 302.41 12.167 299.18 17.064 0.074
Outer inferior macular thickness 277.79 10.755 273.76 16.798 0.045
Outer temporal macular thickness 271.52 10.992 266.23 18.987 0.013
GCL thickness
Superior 84.55 4.323 81.61 7.087 0.032
Superonasal 85.28 4.780 81.04 7.234 0.029
Inferonasal 84.66 5.314 81.82 7.521 0.135
Inferior 84.34 5.052 81.91 6.252 0.389
Inferotemporal 85.79 4.003 83.73 4.860 0.233
Temporal 83.76 3.324 82.27 5.312 0.069
Average IPL+GCL 84.83 4.071 82.73 6.230 0.095
Minimum IPL+GCL 82.45 3.601 80.18 6.194 0.005*
RNFL thickness
Average 96.17 6.714 94.88 11.505 0.105
Superior 117.90 10.965 118.68 16.861 0.115
Nasal 73.59 12.724 72.40 15.182 0.345
Inferior 128.14 14.060 123.20 22.907 0.075
Temporal 64.97 8.218 61.48 10.553 0.027
The asterisk indicates those values with statistical significance after Bonferroni correction for multiple tests (p<0.0055 for macular
measurements; p<0.0062 for ganglion cell measurements and p<0.01 for RNFL measurements).
GCL, ganglion cell layer; HD, high definition; IPL, inner plexiform layer; RNFL, retinal nerve fibre layer.
Figure 1 Correlation between the average macular thickness
and contrast sensitivity vision as measured with the CSV
1000E test, at a spatial frequency of 6 cycles per degree, in
patients with Parkinson’s disease. CSV, contrast sensitivity
vision.
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have been masked and generated a per cent of depend-
ence between measurements.
Previous studies have indicated that patients with PD
lose foveal contrast sensitivity regarding patterns to
which normal observers are most sensitive (ie, requiring
the least contrast for detection).8 9 Ganglion cells in the
retina show adaptation to visual contrast and pool visual
inputs over their receptive fields through an array of par-
allel bipolar cells with smaller receptive fields.22 The par-
vocellular and magnocellular ganglion cells are located
in the retinal ganglion cells (RGC) layer and take two
different pathways for the identification of colour and
Table 4 Correlation between macular and GCL structural measurements and colour vision evaluated with Lanthony colour
test in patients with Parkinson’s disease
Lanthony colour test
C-index p Value CCI p Value S-index p Value
Macular thickness
Central −0.019 0.905 −0.059 0.716 −0.017 0.915
Inner superior −0.146 0.369 −0.119 0.463 −0.167 0.302
Inner nasal −0.055 0.735 −0.044 0.788 −0.040 0.807
Inner inferior −0.073 0.654 −0.064 0.697 −0.074 0.649
Inner temporal −0.049 0.764 −0.031 0.850 −0.126 0.439
Outer superior −0.377 0.017 −0.380 0.015 −0.271 0.090
Outer nasal −0.341 0.031 −0.323 0.042 −0.310 0.051
Outer inferior −0.360 0.022 −0.353 0.025 −0.375 0.017
Outer temporal −0.360 0.023 −0.361 0.022 −0.350 0.027
Macular average −0.691 0.019 −0.657 0.028 −0.709 0.015
Macular volume −0.686 0.020 −0.647 0.032 −0.709 0.015
GCL thickness
Superior −0.380 0.015 −0.369 0.019 −0.287 0.072
Superonasal −0.383 0.015 −0.337 0.033 −0.350 0.027
Inferonasal −0.338 0.033 −0.313 0.049 −0.268 0.094
Inferior −0.341 0.031 −0.311 0.051 −0.282 0.078
Inferotemporal −0.252 0.116 −0.263 0.101 −0.203 0.208
Temporal −0.403 0.010 −0.437 0.005 −0.314 0.048
Average IPL+GCL −0.381 0.015 −0.358 0.023 −0.319 0.045
Minimum IPL+GCL −0.338 0.033 −0.326 0.040 −0.290 0.069
Data in bold type correspond to statistically significant correlations (p<0.05).
CCI, colour confusion index; C-index, confusion index; GCL, ganglion cell layer; IPL, inner plexiform layer; S-index, scatter index.
Figure 2 Correlation between the average macular thickness
and visual acuity as measured with ETDRS optotype at a
contrast level of 100% in patients with Parkinson’s disease.
ETDRS, Early Treatment Diabetic Retinopathy Study.
Figure 3 Correlation between macular volume and visual
acuity as measured with ETDRS optotype at a contrast level
of 100% in patients with Parkinson’s disease. ETDRS, Early
Treatment Diabetic Retinopathy Study.
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contrast at different frequencies.23 RGC loss (as
observed using SD-OCT) was recently identified as the
cause of visual impairment in patients suffering from
another neurodegenerative process, multiple sclerosis.24
Thus, a similar process could be the cause of the con-
trast and colour deficiencies in patients with PD. In add-
ition, in the mammalian retina, colour vision and
contrast sensitivity are modulated through D1 and D2
receptors. These dopaminergic receptors are differen-
tially located in the retinal layers and a complete lack of
activation leads to signal dispersion, and alterations in
colour vision and contrast sensitivity.2
Alteration of the retinal layers in PD was first demon-
strated in 2004.25 Since then, various studies have shown
different results.3–5 25–28 Previous studies performed by
our team confirmed that both macular thickness and
the RNFL were affected in patients with PD, especially
in the inferior and temporal quadrants.4 5 29 Moreover,
Garcia-Martin et al30 demonstrated that the inner retinal
layers were most affected in these patients, and that the
GCL thickness was inversely correlated with disease dur-
ation and PD severity, and was predictive of axonal
damage in these patients. The present study included a
smaller number of patients, which may have affected the
significance of our results compared with previous
studies. We could only detect a significant reduction in
the minimum GCL+IPL thickness in patients with PD
compared with healthy participants, after correction for
multiple comparisons. However, we detected a clear ten-
dency towards a reduction in the macular, RNFL and
GCL thicknesses. A significant reduction in the temporal
sectors of the peripapillary RNFL thickness has been
repeatedly observed by different groups,31 32 and this
reduction was also observed in the present study. Two
recent studies, however, detected no differences in the
peripapillary RNFL thickness of patients with PD com-
pared with healthy controls, using SD-OCT,27 28 and one
study only found significant differences in the nasal
quadrant.33 More studies are required to clarify these
contradictory observations.
In a previous study, we demonstrated that the retinal
thickness corresponding to the papillomacular bundle
(as measured with the Axonal Analytics software for
Spectralis OCT) correlated (r>0.70) with some functional
parameters (such as the mean defect and the pattern SD
of the automated perimetry) in patients with PD.34 The
GCL was not investigated at that time, however, and visual
function parameters were reduced to perimetry and
colour vision was measured with the Ishihara colour test.
The current study evaluated not only the RNFL but also
the GCL thickness, and more visual function parameters
were analysed. The GCL correlated most with the visual
function parameters: GCL thickness was directly asso-
ciated with VA and CSV measured at all different spatial
frequencies, and inversely correlated with the colour
vision indexes. Thus, GCL thinning is linked to colour
deficiencies, contrast sensitivity loss and lower vision at
different contrast levels in patients with PD.
The degree of correlation is usually classified as low
(<0.30), moderate (0.30–0.70) or strong (>0.70). Our
results revealed a low and moderate degree of correl-
ation between most parameters, consistent with findings
in other neurodegenerative diseases.35 Macular thickness
and macular volume, however, were strongly associated
with functional parameters (VA, CS, and Lanthony CCI,
C-index and S-index). This strong association, to the
best of our knowledge, has not been previously demon-
strated in PD.
There are very few studies of the correlation between
functional and structural parameters in patients with
PD. Adam et al14 demonstrated a significant reduction in
the inner retinal layer complex (RNFL+GCL+IPL) in
patients with PD, but no association with contrast sensi-
tivity (measured with the Pelli-Robson chart). A very
recent study by Kaur et al15 demonstrated a correlation
between functional parameters and GCL thinning, con-
sistent with our results. Kaur et al, however, found no sig-
nificant alterations in VA and colour vision in patients
with PD, and the severity of the disease was not corre-
lated with structural parameters, in contrast to other
studies that demonstrate an association between macular
and GCL thickness and disease duration and severity.29 30
Although the severity of the disease in our sample
(based on the Hoehn-Yahr scale) was similar to that in
Kaur’s study, the duration of the disease in our study was
longer than that in Kaur’s study (13 vs 5 years), which
may account for some of the differences in the results
between the two. These discrepancies (and similarities)
support the need for more studies on this topic. Our
results, together with previously published studies,15 30
suggest that the GCL could be a reliable indicator of
structural alterations in the retina of patients with PD,
demonstrating a significant correlation with functional
tests in these patients. The results of the present study
Table 5 Correlation between visual acuity measured with ETDRS chart at different levels of contrast (in %) and macular
structural measurements (thickness and volume) in patients with Parkinson’s disease
Macular thickness p Value Macular volume p Value
VA ETDRS 100 −0.765 0.006 −0.761 0.007
VA ETDRS 1.25 −0.718 0.013 −0.715 0.013
VA ETDRS 2.50 −0.738 0.010 −0.729 0.011
Correlation data in bold type are statistically significant (p<0.05).
ETDRS, Early Treatment Diabetic Retinopathy Study; VA, visual acuity.
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have important implications for clinical diagnosis and
functional deficits in patients with PD, and highlight the
importance of visual function tests in the evaluation of
these patients.
In conclusion, visual dysfunction was significantly cor-
related with morphological parameters in patients with
PD. Patients with PD present with a reduction in GCL
thickness, which is closely associated with visual
dysfunction.
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